Prexton Therapeutics

Prexton Therapeutics is the first spin-off company from EPP Fund. The company is developing programs in Parkinson’s disease focused on targeting the metabotropic glutamate receptors mGluR3 and mGluR4. Prexton Therapeutics is based in Geneva, Switzerland.

Team Members
more about
Jasper Bos
more about
Edward Kliphuis
Latest News Entry
Parkinson’s disease: Prexton announces initiation of phase II clinical testing

Study will evaluate first-in class treatment in six European countries

Prexton Therapeutics Series B financing round raises €29 million ($31M) to advance its novel Parkinson’s therapeutic

Forbion & Seroba co-led funding, forming international consortium of Merck Ventures, Ysios and Sunstone
Funding to finance two Phase II trials in Parkinson’s disease

Geneva, Switzerland and Amsterdam, The Netherlands, February 7, 2017 - Prexton Therapeutics (Prexton), a biopharmaceutical company developing novel therapeutic compounds for the treatment of Central Nervous System (CNS) conditions, today announces the closing of a Series B financing round of €29 million ($31M).

Parkinson’s disease: Prexton Therapeutics completes phase 1 clinical trial

Study shows mGluR4 positive allosteric modulator is safe and well tolerated at doses well above those that produce robust effects in Parkinson’s disease animal models

Parkinson’s disease: Prexton Therapeutics starts phase 1 clinical trial

First clinical trial with an mGluR4 positive allosteric modulator, a first-in-class compound for treating Parkinson’s disease, will assess safety and tolerability.

Prexton Therapeutics raises 8.7 million euros (10 million dollars) in a Series A round

Geneva, Switzerland, February 24 2015 - Prexton Therapeutics, a biopharmaceutical company developing novel therapeutic compounds for the treatment of CNS conditions including ...

all related news
all portfolio news